BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results